Title	Response Assessment
Number of Patients Screened	40
Number of Patients Enrolled	33
Number of Patients Evaluable for Toxicity	32
Number of Patients Evaluated for Efficacy	28
Evaluation Method	RECIST 1.1
Response Assessment CR	n = 1 (4%)
Response Assessment PR	n = 0 (0%)
Response Assessment SD	n = 10 (36%)
Response Assessment PD	n = 16 (57%)
Response Assessment OTHER	n = 1 (4%)
Outcome Notes

Of the 28 efficacy‐evaluable patients treated with SGN‐2FF in part A, a best response of CR was observed in 1 (4%) patient in the 5 g QD dose cohort who had squamous cell carcinoma of the head and neck. The patient had a 100% reduction in tumor burden after 10 cycles (Fig. 4). The objective response rate was 4% (95% confidence interval [CI], 2.5–100), the disease control rate was 39% (95% CI, 71.5–100), and the clinical benefit rate was 18% (95% CI, 47.8–100).